Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
โThe difference is that we overcame the (Eden) cleaning and safety issues and now have a product that is GMP-compatible. That's major!โ โ beartrap
True. Arguably the most important point in yesterdayโs 10Q.
A large pharma industry built on checkpoint profits must be highly appreciative regarding Edenโs delays manifesting themselves repeatedly and conveniently in a slow crawl toward CI patent cliffs.
I could see some boardroom giving a standing ovation when some CEO iterates, โand I especially want to thank NWBO for slowing down their closed system automation development to a decade long snails pace.โ
By the way, some on this message board were discussing stacking these automated machines nearly a decade ago.
(Good thing we are starting with artisan manufacturing.)
First the bears tried to intimidate LL and at the same time allege she had separate allegiances from NWBO.
LL joined NWBOโs Scientific Advisory Board.
Now the bears are trying the same game against UCLA. Gee, wonder how that will work out?
Molasses comes to mind.
First things first.
10Q
Approval decision and MTD decision.
Anyway, just to remind the intelligentsia, we are starting with artisan commercial manufacturing, (if/when approved).
Anybody else a little weirded out by SAVA going meteoric AFTER their scientist was charged with fraud (donโt know how solid case is) and shorts let off hook?
Flashback, a few weeks or so ago, one of the bears, I think it was either Ici, lessismore or learningcurve that suggested NWBO just settle with the seven by getting them to go long.
Hmm.
There are alternative interim methods of funding between any marketing approval and Nice determination.
Zzzzzzzzzzz. SMH.
There are interim alternatives for funding aside from NICE. Clearly, NICE wont be pursued until Eden is ready. IMO.
10Q August 9, 2024.
Tuesday?
MHRA typically schedule inspections after 80 day first phase and after (60 day to 120 day off clock) RFI response, because inspections normally occur in second 70 day phase.
The inspections were not scheduled by the asm, they are now scheduled. Market maker mischief associated with BS rumors regarding NWBO were not known at ASM. Today, they are posited.
Youโre just a price suppressor. I suspect you are a financier. You leave any future speculative multiplier completely out of the equation. Weโre getting our asses kicked right now, but you just keep talking and piling on.
Interesting. โMr. Malik sold 657,895 common stock options to Mr. Jerry Jasinowski, former director of Northwest Biotherapeutics, Inc.โ
Very interesting.
What supplement does he take for his knees? A friend wants to know.
Up the food chain bozo.
Kennny is constantly pitting internal teams against internal teams for performance. Losers get booted off the Citadel. My guess is some of those guys at least know how much whistle blowers can be reimbursed.
No, the Citron case demonstrates how the SEC moves up the food chain. IMO.
In the Citron case, it looks like SEC had help from
1. Financial Industry Regulatory Authority.
https://www.sec.gov/newsroom/press-releases/2024-89#:~:text=The%20Securities%20and%20Exchange%20Commission,his%20supposed%20stock%20trading%20recommendations.
โThe SEC appreciates the assistance of the Financial Industry Regulatory Authority.โ
He is waiting. This is a simpler MTD issue, and it is reasonable, even with summer schedules, that the magistrateโs office should be done around now. Regardless, RRH is waiting just like the rest of us. If the magistrate takes longer than last time, so be it.
Evaluation (clock) started January 24, 2024, according to MHRA.
I played your post backwards and finally understood it.
Sprechen sie geek?
Yes, Coleyโs discovery was interrupted by 130 years, including two World Wars, Chemotherapy, and a pharmaceutical industry that lives to put real answers on the back burner โ exceptions being hepatitis C cure, polio and other vaccines for communicable diseases.
Youโre right, science is ahead of the curve.
You missed my meaning. I did not say he was or wasnโt misdiagnosed. Iโm saying thatโs what the screening process is for. It worked. Beyond that, Nemesis and this inane discussion are just another way to turn off confused investors. IMO.
Sentiment, aside from anything to do with Nemesis, there are hundreds of patients from the DCVax-l trial that were screened but excluded from enrollment because they did not have GBM. Curiously, other company trials like Novocureโs pivotal GBM trial, did not exclude patients during the screening process due to the fact they did not have GBM. Not certain why Nemesis and you keep kicking this can around about someone who was excluded from the NWBO trial because they did not have GBM. It is expected. However, it does provide a long running narrative, just as many other shorts do, to confuse and pound the price down. For shorts or value investors with powder left, I suppose they appreciate such narratives before some important decisions are soon made.
Magistrateโs R&R.
NWBO does not control timing at this stage of the Court case.
My guess is the Court already drafted its decision. Perhaps a vacation here or there delayed all relevant personnel review. I assume a decision will come out this week.
Good one Doc. Youโve alway been an eloquent writer, but this was Hemingway cogent.
Your alias has run its course Pyrr.
Wrong terminology, doc.
This was actually a very informative exchange. Thank you Senti.
One word.
Punitive.
The bears are clinging to what Linda Liau stated is a โcurrentโ (aka โnot permanent) limitation within the FDA system โ necessitating patient level data for eca.
Remember that the UK/MHRA is making their own separate determination from the FDA.
Remember that the MHRA has ten year compassionate data.
Recall that Dr. Ashkan states that the MHRA does not suffer from the same level of corruption as the FDA.
Recall that Dr. Liau formally called out BP, even though she works with them, for their refusal to share patient level data in old GBM trials, thus interfering with the march of scientific progress and patient care within the United States.
There are several reasons why NWBO chose the UK to initiate DCVax-l therapy. The primary one is to bypass greed based roadblocks manifested by the U.S. regulatory industrial complex.
Also recall, LP believes the MHRA has likely chosen to evaluate DCVax-l on the accelerated 150 day pathway. NWBO has stated they have not received bad news during this process. We are 175 days into the MHRA evaluation.